Enter multiple symbols separated by commas

Amgen Inc


  • Warnings Strengthened for Amgen, J&J Anemia Drugs Thursday, 8 Nov 2007 | 1:50 PM ET

    The warning labels have been strengthened on anemia drugs made by Amgen Inc and Johnson & Johnson to reflect concerns they may increase the risk of heart attacks, stroke and death, the companies and U.S. regulators said on Thursday.

  • Market Insider/Wednesday Look Ahead Wednesday, 31 Oct 2007 | 11:23 AM ET

    Buying in tech stocks could lift the market again Wednesday, but Merrill Lynch earnings hang in front of the opening bell like a dark cloud. Or should we say Merrill's report of losses. The firm is scheduled to report third quarter numbers between 7:30 and 8 a.m., and analysts are forecasting a loss of $0.45 per share.

  • Huckman's Drug Headlines Wednesday, 24 Oct 2007 | 7:27 PM ET

    Lots of late news from the drug makers. CNBC’s Mike Huckman has the latest.

  • Amgen Profit Climbs; Aranesp Sales Decline Wednesday, 24 Oct 2007 | 5:41 PM ET

    Amgen's  third-quarter earnings  rose from a year ago and beat forecasts. The biotechnology firm reported a profit of $1.18 billion, or $1.08 a share, on sales of $3.6 billion.

  • Amgen: Is There A Takeout Scenario? Wednesday, 24 Oct 2007 | 1:15 PM ET

    On a day when the markets are selling off, shares of the world's biggest biotech company--by sales--are holding their own. There are a few things that could be buoying Amgen's stock. The company won a huge patent battle yesterday, it reports earnings after the closing bell today and an analyst has upgraded the stock to "Outperform".

  • Glaxo's Avandia Nose Dive: What It Means Wednesday, 24 Oct 2007 | 11:48 AM ET

    Shares in the world's second biggest drug company, GlaxoSmithKline, are giving back all of yesterday's gains in early trading this morning. That's because sales of its embattled diabetes drug, Avandia and other Avandia-related products took a huge dive in the third quarter. Down 48% in the U.S. from the same time last year.

  • Stocks End Broadly Higher Following Late Rally Tuesday, 23 Oct 2007 | 4:01 PM ET

    Stocks ended broadly higher amid continued strength in the tech sector, which gained following Research in Motion's deal to distribute BlackBerry smartphones in China, along with strong earnings reported by Apple.

  • Amgen Wins Patent Suit Over Anemia Drug Tuesday, 23 Oct 2007 | 1:00 PM ET

    A Boston jury Tuesday found  that the patents on Amgen's top-selling anemia drugs are valid, blocking Roche from launching a rival medicine in the United States and sending Amgen shares up more than 2 percent.

  • JNJ, Genentech: What's Ailing Them (And Their Stock) Tuesday, 16 Oct 2007 | 11:44 AM ET

    If you saw the headline, you would've thought that Johnson and Johnson might help power the Dow today. The hybrid pharmaceutical, medical device and consumer healthcare products company handily beat the Street and raised its guidance for the year.

  • Genzyme Shares Jump on Takeover Talk, Drug Data Monday, 15 Oct 2007 | 11:47 AM ET

    Genzyme said Sunday that three-year data from a mid-stage trial of its experimental multiple sclerosis drug showed it to be very effective, but patients must be monitored on a monthly basis to avoid a potentially deadly side effect.

  • Stop Trading!: Amgen's Attractive Thursday, 11 Oct 2007 | 3:36 PM ET

    If the pharma company wins its lawsuit with Roche, investors could do very well with this stock.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Genentech Drops In (Industry) Poll, New Number One! Thursday, 11 Oct 2007 | 2:22 PM ET

    What a week for upsets. First, the 35-game home field winning streak of my USC Trojans comes to an end at the hands of the 40-point underdog Stanford Cardinal. Then, today, Genentech's six-year reign at the top of a big industry survey is over. Boehringer Ingelheim is the new number one!

  • Big Biotech Earnings Surprise? Genentech & Amgen Tuesday, 9 Oct 2007 | 11:01 AM ET

    As we head into the thick of earnings season some analysts are putting out their preview notes for clients. And a couple of interesting ones about the kings of biotech, Genentech and Amgen, have come into my inbox over the past couple of days. Genentech reports after the bell next Monday, October 15. And Amgen comes out, also after the bell, ten days later on the 25th.

  • Fund Manager Picks Biotech, Pharma Stocks Friday, 5 Oct 2007 | 11:44 AM ET

    Scott Richter, portfolio manager with Fifth Third Asset Management, oversees the Fifth Third Disciplined Large Cap Value Fund. The fund is up 8 percent year-to-date and 13 percent over the last three years. The strategist offered CNBC viewers and CNBC.com readers a few of his favorite stocks in the health care and biotechnology sector.

  • Lightning Round: Tribune, Cummins, Amgen and More Tuesday, 25 Sep 2007 | 11:19 AM ET

    Cramer makes the call on viewers' favorite stocks.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Medicare: We Want Proof On Anemia Drugs Monday, 24 Sep 2007 | 2:56 PM ET

    Right on the heels of my previous blog entry about an analyst saying a Medicare reconsideration of its anemia drug reimbursement policy may be in the offing comes this news out of the agency.

  • Medicare Wants Proof for Amgen, J&J Anemia Drugs Monday, 24 Sep 2007 | 2:21 PM ET

    The U.S. Medicare agency said Monday that, unless it receives new evidence, it will not reverse a decision to cut payments for certain uses of anemia drugs, including Amgen's Aranesp.

  • Amgen: Getting a Second Chance From Medicare? Monday, 24 Sep 2007 | 11:37 AM ET

    After being down about half-a-dollar in early trading, volatile shares of Amgen are trimming their loses and heading back into positive territory at this writing. That turnaround could be from the dissemination of a research note from Wachovia biotech analyst George Farmer.

  • Stem Cell Trade Back On? Friday, 21 Sep 2007 | 11:12 AM ET

    Is the stem cell trade back on, ahead of next week’s biotech conference? The traders talk how to play stem cells without investing in risky, small biotech companies.

  • $80 Oil, Record Low Dollar, Stocks Quiet Thursday, 13 Sep 2007 | 3:33 PM ET

    All quiet on the stock market front, but boy were the other markets hopping. Oil touched $80 and the dollar fell to a record low versus the euro. What’s the inside chatter on these events?